GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nutriband Inc (NAS:NTRB) » Definitions » Capex-to-Revenue

Nutriband (Nutriband) Capex-to-Revenue : 0.00 (As of Jan. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Nutriband Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Nutriband's Capital Expenditure for the three months ended in Jan. 2024 was $0.00 Mil. Its Revenue for the three months ended in Jan. 2024 was $0.53 Mil.

Hence, Nutriband's Capex-to-Revenue for the three months ended in Jan. 2024 was 0.00.


Nutriband Capex-to-Revenue Historical Data

The historical data trend for Nutriband's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutriband Capex-to-Revenue Chart

Nutriband Annual Data
Trend Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only - - 0.06 0.04 0.03

Nutriband Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 - - -

Competitive Comparison of Nutriband's Capex-to-Revenue

For the Biotechnology subindustry, Nutriband's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nutriband's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nutriband's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nutriband's Capex-to-Revenue falls into.



Nutriband Capex-to-Revenue Calculation

Nutriband's Capex-to-Revenue for the fiscal year that ended in Jan. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.052) / 2.085
=0.02

Nutriband's Capex-to-Revenue for the quarter that ended in Jan. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.525
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nutriband  (NAS:NTRB) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Nutriband Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nutriband's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Nutriband (Nutriband) Business Description

Traded in Other Exchanges
Address
121 South Orange Avenue, Suite 1500, Orlando, FL, USA, 32801
Nutriband Inc is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Executives
Michael Davidov director 60 EAST 42 STREET, NEW YORK NY 10165
Serguei Melnik director, 10 percent owner, officer: Chief Financial Officer
Gareth Sheridan director, 10 percent owner, officer: CEO 6064 CENTRAL COLLEGE RD., NEW ALBANY OH 43054
Vitalie Botgros director, 10 percent owner, officer: Chairman of the BOD GREGERSTR 36B, FISHAMEND C4 2401